Inve India ▾

Godavari Biorefineries share price & results

Godavari Biorefineries Limited· Fast Moving Consumer Goods

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Integrated bio-refiner converting sugarcane into ethanol, power, bio-based chemicals and Jivana food products.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue558 ₹ crore+4.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin0.1 %−1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-19.0 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity3.67 %+7.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin0.25 %+4.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)7.02 %−4.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 1 judged target kept · 7 open · verdicts reflect calls analysed to Q4 FY26.

Godavari Biorefineries Limited management guidance track record on Inve: 8 targets tracked across analysed earnings calls (1 achieved, 0 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
R&D MilestoneSafety trial is expected to be complete in Q2 FY26.
Call transcript, Q4 FY25 · 26 May 2025
Q4 FY25Q4 FY26:Remains achieved. Company confirms safety trials are complete and is now preparing application to CDSCO for efficacy trials.
Call transcript, Q4 FY26 · 26 May 2026
Achieved
Capacity Commissioning TimelineTargeting for commissioning from Q4 of the coming financial year which is H2 FY26.
Call transcript, Q3 FY25 · 10 Feb 2025
Q3 FY25Q4 FY26:Further delayed. Commissioning trials now expected in June 2026 (Q1 FY27), pushed from the previous target of March/April 2026.
Call transcript, Q4 FY26 · 26 May 2026
Delayed
EBITDA GrowthTargeting an increase in EBITDA by about 3x of FY25 numbers by FY29 (approx INR 360 crores).
Call transcript, Q4 FY25 · 26 May 2025
Q4 FY25Q4 FY26:FY26 EBITDA grew 15.8% YoY to INR 139 crores, a step towards the FY29 goal of ~INR 360 crores. Growth drivers (chemicals, new distillery) are progressing.
Call transcript, Q4 FY26 · 26 May 2026
On Track

Source: Inve Guidance Tracker for Godavari Biorefineries Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Godavari Biorefineries Limited's 8 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 5 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹201.66 +2.35% · +₹4.63

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −24.0% 1Y

₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 26 Feb 2026Q4 FY26 — 26 May 2026

1Y: ₹265.3 on 24 Oct 2025 → ₹201.66. High ₹334.9 (23 Apr 2026), low ₹197.03 (26 Oct 2026).

Previous close
₹197.03
Market cap
₹1.0k Cr
52-week range
₹197.03 – ₹334.9
One year
−22.97%
Price to earnings (TTM to Jun 2026)
35.01×
Return on equity (TTM to Jun 2026)
3.67%

Overview

Symbol
NSE:GODAVARIB
Exchange
NSE
Currency
INR

What Godavari Biorefineries Limited does

Based on the company's own presentations, annual report and earnings calls.

Godavari Biorefineries operates an integrated biorefinery that crushes sugarcane to produce sugar, ethanol and bagasse-based cogeneration power, and separately processes molasses and sugarcane derivatives into bio-based specialty and non-specialty chemicals (such as ethyl acetate, acetic acid, extra neutral alcohol and acetaldehyde) sold to personal care, cosmetics, food, fragrance, fuel, paints, agrochemical and pharmaceutical customers. It also markets packaged sugar, jaggery, salt and spices under its Jivana consumer brand, sells surplus power to the grid, and pursues early-stage drug-discovery research (including an oncology molecule and an antiviral platform) through in-house R&D and a US subsidiary. The company is building a new grain/maize-based ethanol distillery to add fungible ethanol capacity.

Segments

  • Integrated Sugar, Co-generation & Ethanol
  • Bio-Based Chemicals
Manufacturing facilities
2 (Sameerwadi, Karnataka + Sakarwadi, Maharashtra)
Market position
Among India's largest producers of ethanol by volume at a single location
R&D facilities
3 DSIR-registered R&D facilities with 50+ researchers and scientists
Jivana brand retail reach
7,500+ stores
New ethanol capacity under construction
200 KLPD grain/maize-based distillery adding ~60 million litres/year capacity
Drug-discovery subsidiary
Sathgen Therapeutics (US subsidiary for global IP creation and out-licensing)
Founded 1939Headquarters Mumbai, Maharashtra, IndiaEmployees 2,380 (2025-03-31) Company website

How the price took the results

close before → close after

Q4 FY26
−3.1%
26 May
Q3 FY26
+2.3%
26 Feb
Q2 FY26
+3.7%
14 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Godavari Biorefineries Limited

Free account: one company. Everything above stays public.

Write why you follow Godavari Biorefineries Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds